DelveInsight’s, “Frontotemporal Dementia Pipeline Insight 2024” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Frontotemporal Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Frontotemporal Dementia Pipeline. Dive into DelveInsight’s comprehensive report today! @ Frontotemporal Dementia Pipeline Outlook
Key Takeaways from the Frontotemporal Dementia Pipeline Report
- In October 2024:- Sanofi- To assess prevalence of Gaucher disease (GD) diagnosed in pediatric patients presenting with unexplained splenomegaly (SMG) after exclusion of first intention-diagnoses (e.g. portal hypertension, haematological malignancy, hemolytic anemia, infection) based on clinical examination and routine biological tests (full blood count, reticulocytes, liver tests, abdominal ultrasound, Coombs test and Epstein Barr virus serology).
- DelveInsight’s Frontotemporal Dementia pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Frontotemporal Dementia treatment.
- The leading Frontotemporal Dementia Companies such as Transposon Therapeutics, Alector, Vesper Bio, AviadoBio, Passage Bio, Eli Lilly and Company, Coya Therapeutics, Neurimmune Therapeutics, Asceneuron SA., and others
- Promising Frontotemporal Dementia Therapies such as LY3884963, DNL593, AL001, PBFT02. Olipudase alfa, and others
Stay ahead with the most recent pipeline outlook for Frontotemporal Dementia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Frontotemporal Dementia Treatment Drugs
Frontotemporal Dementia Emerging Drugs Profile
- AL001: Alector
AL001 is a recombinant human anti-human sortilin (SORT1) monoclonal IgG1 developed by Alector in partnership with GSK. It aims to increase the level of progranulin in humans by inhibiting a progranulin degradation mechanism. The antibody received orphan drug designation, fast track designation, and breakthrough designation from the US FDA for the treatment of frontotemporal dementia. Alector Inc. is currently investigating AL001 in Phase III clinical trials for FTD with a C9orf72 mutation and granulin mutation.
- TPN-101: Transposon Therapeutics
TPN-101 specifically inhibits the LINE-1 reverse transcriptase that promotes LINE-1 replication. LINE-1 elements are a class of retrotransposable elements that in humans are uniquely capable of replicating and moving to new locations within the genome. When this process becomes dysregulated, LINE-1 reverse transcriptase drives overproduction of LINE-1 DNA, triggering innate immune responses that contribute to neurodegenerative, autoimmune and aging-related disease pathology. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Frontotemporal Dementia.
- AVB-101: AviadoBio
AVB-101 is a potential one-time therapy designed to stop disease progression by delivering a functional copy of the GRN gene to restore appropriate progranulin levels to affected areas of the brain. The drug is delivered using a minimally invasive, stereotactic neurosurgical procedure directly to the part of the brain called the thalamus. The thalamus has extensive connections to other parts of the brain, including the frontal and temporal lobes, which play a critical role in FTD and the symptoms that impact patients and their families. This targeted delivery method aims to safely and effectively cross the blood-brain barrier, delivering targeted treatment directly to the brain to restore progranulin levels in the frontal and temporal cortex where it is needed most, while at the same time minimizing the dose required and thereby limiting any potential systemic exposure. In November 2023, the US Food and Drug Administration (FDA) granted Fast Track designation to AVB-101. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Frontotemporal Dementia.
- VES001: Vesper Bio
VES001 is the first oral, brain penetrant, small molecule sortilin inhibitor designed as a potentially disease-modifying treatment for the neuro-cognitive disorder fronto-temporal dementia (FTD (GRN)). Data returned from this study (NCT06226064) demonstrate the safety and tolerability of VES001 across the full range of doses tested and show it has excellent pharmacokinetics and distribution to relevant parts of the brain. The data predict a once or twice daily efficacious dose. Importantly, volunteers who received VES001 experienced significant and robust increases in levels of progranulin, demonstrating target engagement. Progranulin is a protein known to play a key role in promoting neuron survival, growth and function. People with FTD(GRN) have inherited gene mutations associated with low progranulin levels.
Explore groundbreaking therapies and clinical trials in the Frontotemporal Dementia Pipeline. Access DelveInsight’s detailed report now! @ New Frontotemporal Dementia Drugs
Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Frontotemporal Dementia Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Unveil the future of Frontotemporal Dementia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Frontotemporal Dementia Market Drivers and Barriers
Scope of the Frontotemporal Dementia Pipeline Report
- Coverage- Global
- Frontotemporal Dementia Companies- Transposon Therapeutics, Alector, Vesper Bio, AviadoBio, Passage Bio, Eli Lilly and Company, Coya Therapeutics, Neurimmune Therapeutics, Asceneuron SA., and others.
- Frontotemporal Dementia Therapies- LY3884963, DNL593, AL001, PBFT02. Olipudase alfa, and others
- Frontotemporal Dementia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Frontotemporal Dementia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Frontotemporal Dementia Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Frontotemporal Dementia Companies, Key Products and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- Frontotemporal Dementia: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Frontotemporal Dementia– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Latozinemab: Alector
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- PR 006 : Prevail Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- EXO-050: Coya Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Frontotemporal Dementia Key Companies
- Frontotemporal Dementia Key Products
- Frontotemporal Dementia- Unmet Needs
- Frontotemporal Dementia- Market Drivers and Barriers
- Frontotemporal Dementia- Future Perspectives and Conclusion
- Frontotemporal Dementia Analyst Views
- Frontotemporal Dementia Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/